Skip to Content


In the US, Nivolumab (nivolumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Colorectal Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer and Urothelial Carcinoma.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Monoclonal antibody

Antineoplastic agent: Inhibitor of PD-1 proteins

Chemical Names

A genetically engineered, fully human immunoglobulin G4 (IgG4) mA anti programmed death-1/PD-1 antibody.

Immunoglobulin G4-kappa, anti-[Homo sapiensPDCD1 (programmed cell death 1, PD-1, PD1, CD279)], Homo sapiensmonoclonal antibody; gamma4 haevy chain (1-440) [Homo sapiensVH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (WHO)

Foreign Names

  • Nivolumabum (Latin)
  • Nivolumab (German)
  • Nivolumab (French)
  • Nivolumab (Spanish)

Generic Names

  • Nivolumab (OS: USAN, JAN)
  • BMS-936558 (IS)
  • MDX-1106 (IS)
  • UNII-31YO63LBSN (IS)

Brand Names

  • Nivolumab BMS
    Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb Pharmaceutical, United Kingdom
  • Opdivo
    Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, France; Bristol-Myers Squibb, United States; Bristol-Myers Squibb Pharmaceutical, United Kingdom


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.